Adam Jørring

Boston College - Carroll School of Management

140 Commonwealth Avenue

Chestnut Hill, MA 02467

United States

SCHOLARLY PAPERS

3

DOWNLOADS

797

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (3)

Sharing R&D Risk in Healthcare via FDA Hedges

MIT Sloan Research Paper No. 5194-17
Number of pages: 51 Posted: 03 Apr 2017 Last Revised: 13 Apr 2017
Boston College - Carroll School of Management, Massachusetts Institute of Technology (MIT) - Laboratory for Financial Engineering, University of Chicago, Goldman Sachs and University of Minnesota - Carlson School of Management
Downloads 387 (90,240)

Abstract:

Loading...

Healthcare Finance, R&D Investments, Drug Development, FDA Approval, Idiosyncratic Risk, Risk sharing, Hedging

Sharing R&D Risk in Healthcare Via Fda Hedges

NBER Working Paper No. w23344
Number of pages: 51 Posted: 01 May 2017 Last Revised: 15 Apr 2021
Boston College - Carroll School of Management, Massachusetts Institute of Technology (MIT) - Laboratory for Financial Engineering, University of Chicago, Goldman Sachs and University of Minnesota - Carlson School of Management
Downloads 9 (715,737)

Abstract:

Loading...

2.

Do Mortgage Lenders Compete Locally? Implications for Credit Access

Number of pages: 57 Posted: 01 Mar 2021 Last Revised: 02 Apr 2021
Greg Buchak and Adam Jørring
Stanford University Graduate School of Business and Boston College - Carroll School of Management
Downloads 340 (105,474)

Abstract:

Loading...

mortgage market structure, bank merger policy, household finance

3.

Sharing R&D Risk in Healthcare via FDA Hedges

Becker Friedman Institute for Research in Economics Working Paper No. 2017-01
Number of pages: 51 Posted: 07 Apr 2017 Last Revised: 10 Mar 2021
Boston College - Carroll School of Management, Massachusetts Institute of Technology (MIT) - Laboratory for Financial Engineering, University of Chicago, Goldman Sachs and University of Minnesota - Carlson School of Management
Downloads 61 (415,286)

Abstract:

Loading...

Healthcare Finance, R&D Investments, Drug Development, FDA Approval, Idiosyncratic Risk, Risk sharing, Hedging